Gini F. Fleming, MD

Reversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients.

Therapy for recurrent ovarian cancer is not curative, and presumed overall survival benefits of standard strategies are uncertain and often based on low-level evidence. Treatment toxicity and patient quality of life should be considered at all points during disease management.